Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients… | Phase 3 | terminated | Nov 24, 2008 | GlaxoSmithKline | The study was terminated early following assessment of the two co-primary endpoints showing the… | Efficacy / futility |
| NCT00961844 | Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant… | Phase 1 / Phase 2 | terminated | Aug 19, 2009 | Steinar Aamdal | Logistical problems | Other (stated, no rule matched) |
| NCT03758729 | Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment… | Phase 2 | withdrawn | Nov 29, 2018 | Samsung Medical Center | Internal Issues | Other (stated, no rule matched) |
| NCT03727087 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma | — | terminated | Nov 1, 2018 | Exact Sciences Corporation | COVID-19 | COVID-19 / pandemic |
| NCT02303951 | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC(NEO-VC) | Phase 2 | terminated | Dec 1, 2014 | University Hospital Tuebingen | The main reason for the early termination is the low recruitment rate. | Enrollment / accrual |
| NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain… | Phase 2 | terminated | Nov 2, 2018 | University Hospital Tuebingen | Lack of patients | Other (stated, no rule matched) |
| NCT01683188 | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma(PROCLIVITY01) | Phase 4 | terminated | Sep 11, 2012 | Clinigen, Inc. | slow accrual led to early closure. | Enrollment / accrual |
| NCT00515528 | Vaccination Plus Ontak in Patients With Metastatic Melanoma | Phase 2 | terminated | Aug 13, 2007 | University of Chicago | The immune monitoring data failed to demonstrate an improvement in any biologic endpoint with… | Other (stated, no rule matched) |
| NCT00003509 | Antineoplaston Therapy in Treating Patients With Stage IV Melanoma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 26, 2012 | Pfizer | Study was withdrawn due to scientific and business considerations. | Sponsor / business decision |
| NCT03354962 | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in… | Phase 1 / Phase 2 | terminated | Nov 28, 2017 | Institut Claudius Regaud | Slow recruitment rate | Enrollment / accrual |
| NCT03241927 | Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | Phase 2 | terminated | Aug 8, 2017 | Nina Bhardwaj | difficult enrollment | Enrollment / accrual |
| NCT01280565 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the… | Phase 3 | terminated | Jan 21, 2011 | AB Science | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03972046 | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal… | Phase 2 | withdrawn | Jun 3, 2019 | TriHealth Inc. | Principal investigator leaving study site; no replacement PI will be sought | Investigator |
| NCT02410863 | Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced…(BOTTOM) | Phase 2 | terminated | Apr 8, 2015 | Prof. Dr. med. Dirk Schadendorf | lack of recruitment due to changed therapy options | Enrollment / accrual |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic… | Phase 2 | terminated | Jun 27, 2008 | GlaxoSmithKline | The study was terminated early due to difficulties in recruiting subjects, not following concerns… | Safety / toxicity |
| NCT01942993 | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | Phase 2 | terminated | Sep 16, 2013 | Philip Friedlander | standard of care has changed | Other (stated, no rule matched) |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT00505635 | Biochemotherapy With Temozolomide for Metastatic Melanoma | Phase 2 | terminated | Jul 23, 2007 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | Phase 1 / Phase 2 | terminated | Feb 28, 2013 | Array Biopharma, now a wholly owned subsidiary of Pfizer | The trial was terminated for scientific reasons. | Other (stated, no rule matched) |
| NCT03597282 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in… | Phase 1 | terminated | Jul 24, 2018 | BioNTech US Inc. | Closed due to historically slow enrollment compounded by the COVID-19 pandemic. | COVID-19 / pandemic |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | Phase 1 / Phase 2 | terminated | May 2, 2012 | M.D. Anderson Cancer Center | Accrual slow due to alternate trials and treatment options. | Enrollment / accrual |
| NCT03825913 | 3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With… | N/A | terminated | Feb 1, 2019 | University of Miami | two key faculty members are no longer part of the study and institution | Other (stated, no rule matched) |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT03126461 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | Phase 2 | withdrawn | Apr 24, 2017 | University of Texas Southwestern Medical Center | the project was never initiated and no participants were enrolled, it was closed permanently | Enrollment / accrual |
| NCT01826864 | Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients… | Phase 3 | withdrawn | Apr 9, 2013 | Jonsson Comprehensive Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT02263898 | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have… | Phase 2 | withdrawn | Oct 13, 2014 | Jonsson Comprehensive Cancer Center | closed without enrollment | Enrollment / accrual |
| NCT02889861 | IMCgp100-401 Rollover Study | Phase 2 | terminated | Sep 7, 2016 | Immunocore Ltd | Sponsor decision | Sponsor / business decision |
| NCT04285749 | Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas | Early Phase 1 | withdrawn | Feb 26, 2020 | Case Comprehensive Cancer Center | PI moving to new institution prior to study activation | Other (stated, no rule matched) |
| NCT02336763 | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who… | N/A | terminated | Jan 13, 2015 | Jonsson Comprehensive Cancer Center | Closed due to lack of accrual | Enrollment / accrual |
| NCT03407170 | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma… | Phase 2 | terminated | Jan 23, 2018 | Merck Sharp & Dohme LLC | Lack of Accrual | Enrollment / accrual |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase 1 | terminated | Mar 12, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT00003060 | Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic… | Phase 1 | terminated | Nov 25, 2003 | Louisiana State University Health Sciences Center Shreveport | lack of patient accrual | Enrollment / accrual |
| NCT01308294 | Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients(LAG-3/IMP321) | Phase 1 / Phase 2 | terminated | Mar 4, 2011 | Centre Hospitalier Universitaire Vaudois | Low enrollment rate | Enrollment / accrual |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | Phase 2 | withdrawn | Dec 3, 2019 | Grupo Español Multidisciplinar de Melanoma | The Cediranib producer laboratory decided to stop the development of this product. | Other (stated, no rule matched) |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | Phase 1 | terminated | Aug 22, 2008 | NewLink Genetics Corporation | Lack of enrollment. | Enrollment / accrual |
| NCT03674502 | Safety of ADU-1604 in Adults With Metastatic Melanoma | Phase 1 | terminated | Sep 17, 2018 | Aduro Biotech, Inc. | Study terminated due to business realignment | Sponsor / business decision |
| NCT03565406 | A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With… | Phase 1 | terminated | Jun 21, 2018 | NYU Langone Health | recruiting or enrolling participants has halted prematurely and will not resume; participants are… | Enrollment / accrual |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the… | Phase 1 / Phase 2 | terminated | Jul 9, 2018 | NYU Langone Health | Per regulatory coordinator, the sponsor is no longer supporting the study. | Other (stated, no rule matched) |
| NCT02385669 | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma(Mel62; 6PAC) | Phase 1 / Phase 2 | terminated | Mar 11, 2015 | Craig L Slingluff, Jr | why study stopped | Other (stated, no rule matched) |
| NCT01355562 | Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney… | Phase 2 | withdrawn | May 18, 2011 | Loma Linda University | Primary Investigator is no longer employed at LLU as of 02/29/12. | Investigator |
| NCT02718391 | Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in…(ACDC) | Phase 2 | terminated | Mar 24, 2016 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | The randomization to the observational arm of the trial was no longer ethical | Other (stated, no rule matched) |
| NCT02968680 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous… | Phase 1 | terminated | Nov 18, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT01313429 | Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell… | Phase 1 | terminated | Mar 11, 2011 | National Cancer Institute (NCI) | Per stopping rule if 12 patients underwent immune response analysis after 6 vaccinations and none… | Enrollment / accrual |
| NCT03338777 | Suicide Plus Immune Gene Therapy for Advanced Melanoma(IGTM-101) | Early Phase 1 | terminated | Nov 9, 2017 | Hospital Italiano de Buenos Aires | Failure to achieve primary objective | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 5, 2021source: clinicaltrials